Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-01
DOI
10.1186/s10194-022-01498-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- (2022) Luigi Francesco Iannone et al. CNS DRUGS
- Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine
- (2022) Luigi Francesco Iannone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Association between response to triptans and response to erenumab: real-life data
- (2021) Ilaria Frattale et al. JOURNAL OF HEADACHE AND PAIN
- Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
- (2021) Konstantina Drellia et al. CEPHALALGIA
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Migraine: disease characterisation, biomarkers, and precision medicine
- (2021) Messoud Ashina et al. LANCET
- Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
- (2021) Xing Wang et al. Frontiers in Pharmacology
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
- (2021) Sara Bottiroli et al. JOURNAL OF HEADACHE AND PAIN
- CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
- (2021) Fenne Vandervorst et al. JOURNAL OF HEADACHE AND PAIN
- Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
- (2021) Raffaele Ornello et al. Frontiers in Neurology
- Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients
- (2020) Piero Barbanti et al. CEPHALALGIA
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
- (2020) Fabrizio Vernieri et al. NEUROLOGICAL SCIENCES
- Migraineurs’ psychological traits do not influence response to erenumab
- (2020) Claudia Altamura et al. NEUROLOGICAL SCIENCES
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention
- (2019) Scott G. Garland et al. ANNALS OF PHARMACOTHERAPY
- CGRP and the Trigeminal System in Migraine
- (2019) Smriti Iyengar et al. HEADACHE
- Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class
- (2019) Richard Hargreaves et al. HEADACHE
- How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patientʼs perspective
- (2019) Marta Torres-Ferrus et al. CURRENT OPINION IN NEUROLOGY
- Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number?
- (2019) Piero Barbanti et al. HEADACHE
- Predictors of response to onabotulinumtoxin A in chronic migraine
- (2018) P. Barbanti et al. EUROPEAN JOURNAL OF NEUROLOGY
- Precision Medicine: From Science To Value
- (2018) Geoffrey S. Ginsburg et al. HEALTH AFFAIRS
- The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
- (2017) Smriti Iyengar et al. PAIN
- The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients
- (2016) P Barbanti et al. CEPHALALGIA
- Are migraine endophenotypes needed?
- (2016) Jes Olesen Nature Reviews Neurology
- Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like
- (2014) Piero Barbanti et al. HEADACHE
- The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study
- (2014) Dyveke T. Demant et al. PAIN
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- Reappraising neuropathic pain in humans—how symptoms help disclose mechanisms
- (2013) Andrea Truini et al. Nature Reviews Neurology
- Headache Direction and Aura Predict Migraine Responsiveness to Rimabotulinumtoxin B
- (2012) Patrick M. Grogan et al. HEADACHE
- Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial
- (2012) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- Calcitonin gene-related peptide: A molecular link between obesity and migraine?
- (2010) A. Recober et al. DRUG NEWS & PERSPECTIVES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation